001     286099
005     20240423102733.0
024 7 _ |a 10.1200/JCO.23.01101
|2 doi
024 7 _ |a pmid:38079601
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:157397664
|2 altmetric
037 _ _ |a DKFZ-2023-02675
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Timmins, Iain R
|0 0000-0002-8761-582X
|b 0
245 _ _ |a International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts.
260 _ _ |a Alexandria, Va.
|c 2024
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1713860805_6082
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Mar 10;42(8):927-939
520 _ _ |a There is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this study was to examine the association of physical activity with the risk of developing premenopausal breast cancer.We pooled individual-level data on self-reported leisure-time physical activity across 19 cohort studies comprising 547,601 premenopausal women, with 10,231 incident cases of breast cancer. Multivariable Cox regression was used to estimate hazard ratios (HRs) and 95% CIs for associations of leisure-time physical activity with breast cancer incidence. HRs for high versus low levels of activity were based on a comparison of risk at the 90th versus 10th percentiles of activity. We assessed the linearity of the relationship and examined subtype-specific associations and effect modification across strata of breast cancer risk factors, including adiposity.Over a median 11.5 years of follow-up (IQR, 8.0-16.1 years), high versus low levels of leisure-time physical activity were associated with a 6% (HR, 0.94 [95% CI, 0.89 to 0.99]) and a 10% (HR, 0.90 [95% CI, 0.85 to 0.95]) reduction in breast cancer risk, before and after adjustment for BMI, respectively. Tests of nonlinearity suggested an approximately linear relationship (Pnonlinearity = .94). The inverse association was particularly strong for human epidermal growth factor receptor 2-enriched breast cancer (HR, 0.57 [95% CI, 0.39 to 0.84]; Phet = .07). Associations did not vary significantly across strata of breast cancer risk factors, including subgroups of adiposity.This large, pooled analysis of cohort studies adds to evidence that engagement in higher levels of leisure-time physical activity may lead to reduced premenopausal breast cancer risk.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Jones, Michael E
|b 1
700 1 _ |a O'Brien, Katie M
|0 0000-0003-0643-3790
|b 2
700 1 _ |a Adami, Hans-Olov
|0 0000-0001-9592-5791
|b 3
700 1 _ |a Aune, Dagfinn
|0 0000-0002-4533-1722
|b 4
700 1 _ |a Baglietto, Laura
|0 0000-0002-8193-7529
|b 5
700 1 _ |a Bertrand, Kimberly A
|0 0000-0002-4565-7618
|b 6
700 1 _ |a Brantley, Kristen D
|0 0000-0003-0084-4775
|b 7
700 1 _ |a Chen, Yu
|b 8
700 1 _ |a Clague DeHart, Jessica
|0 0000-0002-2298-3146
|b 9
700 1 _ |a Clendenen, Tess V
|0 0000-0003-4170-6977
|b 10
700 1 _ |a Dossus, Laure
|0 0000-0003-2716-5748
|b 11
700 1 _ |a Eliassen, A Heather
|0 0000-0002-3961-6609
|b 12
700 1 _ |a Fletcher, Olivia
|0 0000-0001-9387-7116
|b 13
700 1 _ |a Fournier, Agnès
|0 0000-0001-8380-3439
|b 14
700 1 _ |a Håkansson, Niclas
|0 0000-0001-7673-5554
|b 15
700 1 _ |a Hankinson, Susan E
|b 16
700 1 _ |a Houlston, Richard S
|0 0000-0002-5268-0242
|b 17
700 1 _ |a Joshu, Corinne E
|0 0000-0002-5100-172X
|b 18
700 1 _ |a Kirsh, Victoria A
|0 0000-0003-2422-2225
|b 19
700 1 _ |a Kitahara, Cari M
|0 0000-0001-6416-4432
|b 20
700 1 _ |a Koh, Woon-Puay
|b 21
700 1 _ |a Linet, Martha S
|0 0000-0002-1687-5587
|b 22
700 1 _ |a Park, Hannah Lui
|0 0000-0001-9973-1396
|b 23
700 1 _ |a Lynch, Brigid M
|0 0000-0001-8060-547X
|b 24
700 1 _ |a May, Anne M
|0 0000-0003-0643-3790
|b 25
700 1 _ |a Mellemkjær, Lene
|0 0000-0001-9222-6215
|b 26
700 1 _ |a Milne, Roger L
|0 0000-0001-5764-7268
|b 27
700 1 _ |a Palmer, Julie R
|0 0000-0002-6534-335X
|b 28
700 1 _ |a Ricceri, Fulvio
|b 29
700 1 _ |a Rohan, Thomas E
|b 30
700 1 _ |a Ruddy, Kathryn J
|0 0000-0001-6298-332X
|b 31
700 1 _ |a Sánchez, Maria-Jose
|0 0000-0003-4817-0757
|b 32
700 1 _ |a Shu, Xiao-Ou
|0 0000-0002-0711-8314
|b 33
700 1 _ |a Smith-Byrne, Karl
|b 34
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 35
|u dkfz
700 1 _ |a Sund, Malin
|0 0000-0002-7516-9543
|b 36
700 1 _ |a Vachon, Celine M
|0 0000-0002-1962-9322
|b 37
700 1 _ |a Vatten, Lars J
|0 0000-0003-2333-5252
|b 38
700 1 _ |a Visvanathan, Kala
|0 0000-0002-0582-8005
|b 39
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 40
700 1 _ |a Willett, Walter C
|0 0000-0003-1458-7597
|b 41
700 1 _ |a Wolk, Alicja
|0 0000-0001-7387-6845
|b 42
700 1 _ |a Yuan, Jian-Min
|b 43
700 1 _ |a Zheng, Wei
|0 0000-0003-1226-070X
|b 44
700 1 _ |a Nichols, Hazel B
|0 0000-0003-0972-1560
|b 45
700 1 _ |a Sandler, Dale P
|0 0000-0002-6776-0018
|b 46
700 1 _ |a Swerdlow, Anthony J
|b 47
700 1 _ |a Schoemaker, Minouk J
|b 48
773 _ _ |a 10.1200/JCO.23.01101
|g p. JCO.23.01101
|0 PERI:(DE-600)2005181-5
|n 8
|p 927-939
|t Journal of clinical oncology
|v 42
|y 2024
|x 0732-183X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:286099
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 35
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b J CLIN ONCOL : 2022
|d 2023-10-22
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21